---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286905297.md"
description: "Relay Therapeutics shares are trading higher after the company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition."
datetime: "2026-05-19T11:34:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286905297.md)
  - [en](https://longbridge.com/en/news/286905297.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286905297.md)
---

# 

Relay Therapeutics shares are trading higher after the company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies signaling the advantage of PI3Kα mutant-selective inhibition.

### Related Stocks

- [RLAY.US](https://longbridge.com/en/quote/RLAY.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders](https://longbridge.com/en/news/286947243.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [BUZZ-Relay Therapeutics drops on $175 mln stock offering](https://longbridge.com/en/news/286962133.md)
- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)